Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Mayo Clinic
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
74High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07650240CT.gov Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial | — | Not Yet Recruiting | — | — | — |
NCT07620574CT.gov Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study | — | Not Yet Recruiting | — | — | — |
NCT07339267CT.gov A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer | — | Recruiting | — | — | — |
NCT07299292CT.gov Castration With Abiraterone 250 mg Without LHRH Analogs or Blockers in Patients With Prostate Cancer Requiring Hormonal Intensification (Multicenter Phase 2) | — | Recruiting | — | — | — |
NCT05361915CT.gov Study to Assess Abivertinib in Combination With Abiraterone in Metastatic Castration Resistant Prostate Cancer | — | Suspended | — | — | — |
NCT06952803CT.gov A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | — | Recruiting | — | — | — |
NCT06991556CT.gov An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | — | Recruiting | — | — | — |
NCT07005154CT.gov A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | — | Recruiting | — | — | — |
NCT06925737CT.gov A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | — | Recruiting | — | — | — |
NCT06527690CT.gov Race Impact on Efficacy of Niraparib Plus Abiraterone Acetate and Prednisone in Patients With Homologous Repair Deficient Castration-resistant Prostate Cancer | — | Withdrawn | — | — | — |
Show 168 more trialsShow fewer
NCT06094842CT.gov Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer | — | Withdrawn | — | — | — |
NCT06652607CT.gov PSA Biochemical Response as Prognostic Factor in Metastatic Castration-Sensitive Prostate Cancer | — | Recruiting | — | — | — |
NCT06689163CT.gov A Study for the Treatment of Metastatic Prostate Cancer With HRS-1167 Tablets Combined With Abiraterone Acetate Tablets and Prednisone | — | Recruiting | — | — | — |
NCT06384222CT.gov Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone | — | Recruiting | — | — | — |
NCT06568094CT.gov A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT06505278CT.gov The Impact of Medication Timing Adjustment on the Effect of Novel Hormonal Therapy | — | Not Yet Recruiting | — | — | — |
NCT06457919CT.gov A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer | — | Recruiting | — | — | — |
NCT06378866CT.gov Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial | — | Recruiting | — | — | — |
NCT05689021CT.gov CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations | — | Active Not Recruiting | — | — | — |
NCT05574712CT.gov A Neoadjuvant Study of Abiraterone Acetate, Leuprolide Acetate, and Belzutifan in Men With Regional Prostate Cancer | — | Withdrawn | — | — | — |
NCT06134271CT.gov Rezvilutamide Plus Abiraterone for Metastatic Hormone-sensitive Prostate Cancer | — | Unknown | — | — | — |
NCT06173362CT.gov Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT06099990CT.gov Dalpiciclib Isethionate Tablets Combined With Abiraterone Acetate Tablets (I) and Prednisone Tablets (AA-P) Versus Placebo Combined With AA-P in Treatment of High-volume, Metastatic, Hormone-sensitive Prostate Cancer (mHSPC) | — | Not Yet Recruiting | — | — | — |
NCT05848011CT.gov A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT05733351CT.gov Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer | — | Terminated | — | — | — |
NCT05818683CT.gov A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT05751941CT.gov Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT05705700CT.gov Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP) | — | Withdrawn | — | — | — |
NCT05288166CT.gov A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer) | — | Active Not Recruiting | — | — | — |
NCT05167175CT.gov The Study of Olaparib Combined With Abiraterone and Prednisone in mHSPC Patients With HRR Gene Mutation | — | Unknown | — | — | — |
NCT04812366CT.gov Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer | — | Recruiting | — | — | — |
NCT04947254CT.gov Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT04729114CT.gov A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | — | Recruiting | — | — | — |
NCT04748042CT.gov Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON) | — | Active Not Recruiting | — | — | — |
NCT04734730CT.gov Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer | — | Recruiting | — | — | — |
NCT05223582CT.gov Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial | — | Unknown | — | — | — |
NCT04677855CT.gov Study of PCUR-101 in Combination With ADT in Patients With mCRPC | — | Terminated | — | — | — |
NCT04296578CT.gov Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone | — | Withdrawn | — | — | — |
NCT04267887CT.gov Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03777982CT.gov Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT | — | Terminated | — | — | — |
NCT03878524CT.gov Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | — | Terminated | — | — | — |
NCT04207255CT.gov Addition of Opaganib to Androgen Antagonists in Patients With mCRPC | — | Completed | — | — | — |
NCT04221542CT.gov Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | — | Recruiting | — | — | — |
NCT04291664CT.gov PK and Dose Escalation and Expansion Study of DST-2970 | — | Terminated | — | — | — |
NCT04220398CT.gov Neoadjuvant Chemo-hormonal Therapy Combined With Radical Prostatectomy for Locally Advanced Prostate Cancer | — | Unknown | — | — | — |
NCT04087174CT.gov A Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination With Novel Agents in Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT03821792CT.gov Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03860987CT.gov Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer | — | Completed | — | — | — |
NCT02789878CT.gov Neoadjuvant Androgen Deprivation Therapy Plus Abiraterone With or Without Apalutamide for High-Risk Prostate Cancer | — | Completed | — | — | — |
NCT03706365CT.gov A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03678025CT.gov Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | — | Recruiting | — | — | — |
NCT03511196CT.gov Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT03298087CT.gov Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer | — | Completed | — | — | — |
NCT03436654CT.gov Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma | — | Active Not Recruiting | — | — | — |
NCT03360721CT.gov Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT03418324CT.gov Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy | — | Completed | — | — | — |
NCT03338790CT.gov An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer | — | Completed | — | — | — |
NCT03141671CT.gov Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509) | — | Unknown | — | — | — |
NCT03279250CT.gov Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer | — | Completed | — | — | — |
NCT02867020CT.gov Study of Abiraterone Acetate Plus ADT Versus APALUTAMIDE Versus Abiraterone and APALUTAMIDE in Patients With Advanced Prostate Cancer With Non-castrate Testosterone Levels | — | Completed | — | — | — |
NCT03263650CT.gov Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC | — | Completed | — | — | — |
NCT03098836CT.gov Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer | — | Completed | — | — | — |
NCT03093272CT.gov A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT03016741CT.gov Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02985957CT.gov A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) | — | Completed | — | — | — |
NCT02849990CT.gov A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy | — | Completed | — | — | — |
NCT03009981CT.gov A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer | — | Completed | — | — | — |
NCT02903160CT.gov Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC) | — | Completed | — | — | — |
NCT03012321CT.gov Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects | — | Active Not Recruiting | — | — | — |
NCT02960022CT.gov A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | — | Recruiting | — | — | — |
NCT02903368CT.gov Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy | — | Completed | — | — | — |
NCT02807805CT.gov Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02543255CT.gov Anti-Androgens and Cabazitaxel in Defining Complete Response in Prostatectomy (ACDC Trial) | — | Completed | — | — | — |
NCT02772588CT.gov AASUR in High Risk Prostate Cancer | — | Completed | — | — | — |
NCT02758132CT.gov Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases | — | Terminated | — | — | — |
NCT02685267CT.gov Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT02494921CT.gov LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC | — | Completed | — | — | — |
NCT02522715CT.gov Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer | — | Active Not Recruiting | — | — | — |
NCT02366494CT.gov Micro RNAs to Predict Response to Androgen Deprivation Therapy | — | Completed | — | — | — |
NCT02344017CT.gov Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02268175CT.gov Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | — | Completed | — | — | — |
NCT02159690CT.gov A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy | — | Withdrawn | — | — | — |
NCT02218606CT.gov Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02182622CT.gov LDE225 + Docetaxel/Prednisone for Adv/Met Castrate Resistant Prostate Cancer w/ Disease Progression After Docetaxel | — | Withdrawn | — | — | — |
NCT01994590CT.gov Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | — | Terminated | — | — | — |
NCT02077634CT.gov Trial of Abiraterone Acetate Plus LHRH-therapy Versus Abiraterone Acetate Sparing LHRH-therapy in Patients With Progressive Chemotherapy-naïve Castration-resistant Prostate Cancer (SPARE) | — | Completed | — | — | — |
NCT02097303CT.gov Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis | — | Completed | — | — | — |
NCT01995058CT.gov Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC | — | Terminated | — | — | — |
NCT02049190CT.gov Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer | — | Unknown | — | — | — |
NCT01949337CT.gov Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer | — | Unknown | — | — | — |
NCT01946165CT.gov Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide | — | Completed | — | — | — |
NCT01995513CT.gov Safety Study of Continued Enzalutamide Treatment In Prostate Cancer Patients | — | Completed | — | — | — |
NCT01848067CT.gov Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT02928432CT.gov SWITCH: Study of the Prednisone to Dexamethasone Change in mCRPC Patients Treated With Abiraterone | — | Completed | — | — | — |
NCT01828476CT.gov Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer | — | Terminated | — | — | — |
NCT01816048CT.gov NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis | — | Terminated | — | — | — |
NCT01809691CT.gov S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT01792687CT.gov Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate | — | Completed | — | — | — |
NCT01751451CT.gov 3-arm Study of Abiraterone Acetate Alone, Abiraterone Acetate Plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients With Prostate Cancer With a Rising PSA or a Rising PSA and Nodal Disease Following Definitive Radical Prostatectomy | — | Completed | — | — | — |
NCT01619813CT.gov Reolysin Combined With Docetaxel and Prednisone or Docetaxel and Prednisone Alone in Metastatic Castration Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01681433CT.gov OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone | — | Terminated | — | — | — |
NCT01741753CT.gov BKM120+Abiraterone Acetate for Metastatic CRPC | — | Terminated | — | — | — |
NCT01685268CT.gov A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate | — | Completed | — | — | — |
NCT01685125CT.gov Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | — | Unknown | — | — | — |
NCT01666314CT.gov Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01578655CT.gov Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer | — | Completed | — | — | — |
NCT01649635CT.gov Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer | — | Completed | — | — | — |
NCT01605227CT.gov Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100 | — | Completed | — | — | — |
NCT01469338CT.gov Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel | — | Terminated | — | — | — |
NCT01546987CT.gov Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer | — | Completed | — | — | — |
NCT01549951CT.gov Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01574937CT.gov XL-184+Abiraterone in Post-Chemo CRPC | — | Completed | — | — | — |
NCT01576172CT.gov Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01591122CT.gov Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01522443CT.gov Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer | — | Terminated | — | — | — |
NCT01511536CT.gov Cabazitaxel and Abiraterone Acetate in Patients With Metastatic Castrate-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01553188CT.gov AMG 386 and Abiraterone for Advanced Prostate Cancer | — | Completed | — | — | — |
NCT01485861CT.gov Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy | — | Completed | — | — | — |
NCT01468532CT.gov Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01393730CT.gov Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01400555CT.gov A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | — | Completed | — | — | — |
NCT01385228CT.gov Pazopanib, Docetaxel, Prednisone Prostate | — | Completed | — | — | — |
NCT01314118CT.gov IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen | — | Completed | — | — | — |
NCT01254864CT.gov Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies | — | Completed | — | — | — |
NCT01087580CT.gov Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer | — | Withdrawn | — | — | — |
NCT01254513CT.gov Feasibility of a Chemotherapy With Docetaxel-Prednisone for Castration-resistant Metastatic Prostate Cancer Elderly Patients | — | Completed | — | — | — |
NCT01193257CT.gov Study Comparing Orteronel Plus Prednisone in Participants With Metastatic Castration-Resistant Prostate Cancer. | — | Completed | — | — | — |
NCT01188187CT.gov Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer | — | Completed | — | — | — |
NCT01204710CT.gov A Study of Olaratumab (IMC-3G3) in Prostate Cancer | — | Completed | — | — | — |
NCT01193244CT.gov Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01145508CT.gov Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | — | Terminated | — | — | — |
NCT01084655CT.gov Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer | — | Completed | — | — | — |
NCT01046916CT.gov Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen | — | Completed | — | — | — |
NCT01155791CT.gov Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer | — | Terminated | — | — | — |
NCT01023061CT.gov Abiraterone Prednisone and Hormonal Therapy Before and During Radiation Therapy in Localized Prostate Cancer | — | Completed | — | — | — |
NCT01051570CT.gov Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel | — | Completed | — | — | — |
NCT00879619CT.gov Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients | — | Terminated | — | — | — |
NCT00916123CT.gov Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer | — | Completed | — | — | — |
NCT00770848CT.gov AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer | — | Completed | — | — | — |
NCT00683475CT.gov A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer | — | Completed | — | — | — |
NCT00751205CT.gov Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC) | — | Completed | — | — | — |
NCT00642018CT.gov A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer | — | Completed | — | — | — |
NCT00634647CT.gov Satraplatin and Prednisone to Treat Prostate Cancer | — | Completed | — | — | — |
NCT00663832CT.gov A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer | — | Completed | — | — | — |
NCT00527124CT.gov Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | — | Terminated | — | — | — |
NCT00466440CT.gov A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients | — | Completed | — | — | — |
NCT00514267CT.gov An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors | — | Completed | — | — | — |
NCT00503984CT.gov A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients | — | Terminated | — | — | — |
NCT00465725CT.gov A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT00450970CT.gov Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) | — | Terminated | — | — | — |
NCT00385827CT.gov A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC) | — | Terminated | — | — | — |
NCT00436956CT.gov AZD2171 to Treat Prostate Cancer | — | Completed | — | — | — |
NCT00627354CT.gov Mitoxantrone, Etoposide, and Vinorelbine As Second-Line Therapy in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | — | Completed | — | — | — |
NCT00350051CT.gov ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer | — | Completed | — | — | — |
NCT00134056CT.gov S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy | — | Completed | — | — | — |
NCT00327340CT.gov Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC | — | Completed | — | — | — |
NCT00331344CT.gov Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy | — | Completed | — | — | — |
NCT00459186CT.gov The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer | — | Completed | — | — | — |
NCT00258388CT.gov Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy | — | Completed | — | — | — |
NCT00268593CT.gov Pilot Efficacy Study of PI-88 With Docetaxel to Treat Prostate Cancer | — | Completed | — | — | — |
NCT00268476CT.gov Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy | — | Active Not Recruiting | — | — | — |
NCT00133224CT.gov Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients | — | Terminated | — | — | — |
NCT00293371CT.gov Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer | — | Terminated | — | — | — |
NCT00087165CT.gov GTI-2040, Docetaxel, and Prednisone in Treating Patients With Prostate Cancer | — | Completed | — | — | — |
NCT00182741CT.gov Calcitriol, Mitoxantrone, and Prednisone in Treating Patients With Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00089856CT.gov GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer | — | Terminated | — | — | — |
NCT00124566CT.gov Study of Irofulven in Patients With Hormone-refractory Prostate Cancer | — | Completed | — | — | — |
NCT00072930CT.gov MEDI-522 in the Treatment of Patients With Metastatic Androgen-Independent Prostate Cancer | — | Completed | — | — | — |
NCT00069745CT.gov Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen | — | Completed | — | — | — |
NCT00058084CT.gov Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00024167CT.gov Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer | — | Terminated | — | — | — |
NCT00004124CT.gov S9921, Hormone Therapy With or Without Mitoxantrone and Prednisone in Patients Who Have Undergone Radical Prostatectomy for Prostate Cancer | — | Completed | — | — | — |
NCT00004001CT.gov S9916, Combination Therapy in Treating Patients With Advanced Prostate Cancer That Has Not Responded to Hormone Therapy | — | Completed | — | — | — |
NCT00004071CT.gov Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer | — | Completed | — | — | — |
NCT00003633CT.gov Combination Chemotherapy in Treating Patients With Advanced Prostate Cancer | — | Unknown | — | — | — |
NCT00003343CT.gov Chemotherapy in Treating Patients Who Have Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00003232CT.gov Combination Chemotherapy in Treating Pain in Hormone Refractory Metastatic Prostate Cancer | — | Completed | — | — | — |
NCT00811031CT.gov Preoperative Docetaxel for Localized Progressive Castration-resistant Prostate Cancer (CRPC) | — | Withdrawn | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Prostate Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Prednisone (this asset) | Mayo Clinic | Approved | BB · 68 |
| Avodart | Bay State Clinical Trials, Inc. | P4 | BBB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Propofol | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Degarelix | Bayer | P4 | BBB |
| Flotufolastat F 18 | Washington University School of Medicine | P4 | BB |
| AVOLVE | Masonic Cancer Center, University of Minnesota | P4 | BB |
| Estramustine | The University of Texas Health Science Center, Houston | P3 | BB |
| Pasireotide | RECORDATI GROUP | P4 | BB |
+42 more in the Prostate Cancer cohort
Other indications for Prednisone
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 74 |
| Diffuse Large B-Cell Lymphoma | — | P4 | BBB · 74 |
| Peripheral T-Cell Lymphoma, Not Otherwise Specified | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Prednisone in Prostate Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/prednisone-prostate-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →